BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun S, Poon RT, Lee NP, Yeung C, Chan KL, Ng IO, Day PJ, Luk JM. Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (<or=2 cm). J Proteome Res 2010;9:1923-30. [PMID: 20121168 DOI: 10.1021/pr901085z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Wong KF, Luk JM. Discovery of lamin B1 and vimentin as circulating biomarkers for early hepatocellular carcinoma. Methods Mol Biol 2012;909:295-310. [PMID: 22903723 DOI: 10.1007/978-1-61779-959-4_19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
2 Wang WW, Ang SF, Kumar R, Heah C, Utama A, Tania NP, Li H, Tan SH, Poo D, Choo SP, Chow WC, Tan CK, Toh HC. Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma. PLoS One 2013;8:e68904. [PMID: 23874805 DOI: 10.1371/journal.pone.0068904] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
3 Zhang QY, Chen H, Lin Z, Lin JM. Chemiluminescence enzyme immunoassay based on magnetic nanoparticles for detection of hepatocellular carcinoma marker glypican-3. J Pharm Anal 2011;1:166-74. [PMID: 29403695 DOI: 10.1016/j.jpha.2011.06.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
4 Triozzi PL, Singh AD. Blood biomarkers for uveal melanoma. Future Oncol 2012;8:205-15. [PMID: 22335584 DOI: 10.2217/fon.11.150] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Ivanovska I, Zhang C, Liu AM, Wong KF, Lee NP, Lewis P, Philippar U, Bansal D, Buser C, Scott M, Mao M, Poon RT, Fan ST, Cleary MA, Luk JM, Dai H. Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma. PLoS One 2011;6:e24582. [PMID: 21949730 DOI: 10.1371/journal.pone.0024582] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
6 Lu JW, Sun Y, Lin LI, Liu D, Gong Z. Exacerbation of Liver Tumor Metastasis in twist1a+/xmrk+ Double Transgenic Zebrafish following Lipopolysaccharide or Dextran Sulphate Sodium Exposure. Pharmaceuticals (Basel) 2021;14:867. [PMID: 34577566 DOI: 10.3390/ph14090867] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Pan TL, Wang PW, Huang CC, Yeh CT, Hu TH, Yu JS. Network analysis and proteomic identification of vimentin as a key regulator associated with invasion and metastasis in human hepatocellular carcinoma cells. J Proteomics 2012;75:4676-92. [PMID: 22387118 DOI: 10.1016/j.jprot.2012.02.017] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
9 Guo Z, Hao T, Wang S, Gan N, Li X, Wei D. Electrochemiluminescence immunosensor for the determination of ag alpha fetoprotein based on energy scavenging of quantum dots. Electrochemistry Communications 2012;14:13-6. [DOI: 10.1016/j.elecom.2011.10.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
10 Megger DA, Bracht T, Kohl M, Ahrens M, Naboulsi W, Weber F, Hoffmann AC, Stephan C, Kuhlmann K, Eisenacher M, Schlaak JF, Baba HA, Meyer HE, Sitek B. Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study. Mol Cell Proteomics 2013;12:2006-20. [PMID: 23462207 DOI: 10.1074/mcp.M113.028027] [Cited by in Crossref: 81] [Cited by in F6Publishing: 40] [Article Influence: 10.1] [Reference Citation Analysis]
11 Fatima S, Luk JM, Poon RT, Lee NP. Dysregulated expression of dickkopfs for potential detection of hepatocellular carcinoma. Expert Rev Mol Diagn 2014;14:535-48. [PMID: 24809435 DOI: 10.1586/14737159.2014.915747] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
12 Arko-Boham B, Lomotey JT, Tetteh EN, Tagoe EA, Aryee NA, Owusu EA, Okai I, Blay RM, Clegg-Lamptey JN. Higher serum concentrations of vimentin and DAKP1 are associated with aggressive breast tumour phenotypes in Ghanaian women. Biomark Res 2017;5:21. [PMID: 28616237 DOI: 10.1186/s40364-017-0100-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Chan CM, Lai KKY, Ng EKO, Kiang MN, Kwok TWH, Wang HK, Chan KW, Law TT, Tong DK, Chan KT, Lee NP, Law S. Serum microRNA-193b as a promising biomarker for prediction of chemoradiation sensitivity in esophageal squamous cell carcinoma patients. Oncol Lett 2018;15:3273-80. [PMID: 29435069 DOI: 10.3892/ol.2017.7698] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
14 Thalla DG, Jung P, Bischoff M, Lautenschläger F. Role of Extracellular Vimentin in Cancer-Cell Functionality and Its Influence on Cell Monolayer Permeability Changes Induced by SARS-CoV-2 Receptor Binding Domain. Int J Mol Sci 2021;22:7469. [PMID: 34299089 DOI: 10.3390/ijms22147469] [Reference Citation Analysis]
15 Zhu J, Warner E, Parikh ND, Lubman DM. Glycoproteomic markers of hepatocellular carcinoma-mass spectrometry based approaches. Mass Spectrom Rev 2019;38:265-90. [PMID: 30472795 DOI: 10.1002/mas.21583] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
16 Beudeker BJB, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Therap Adv Gastroenterol 2020;13:1756284820931734. [PMID: 32647536 DOI: 10.1177/1756284820931734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
17 Kimhofer T, Fye H, Taylor-Robinson S, Thursz M, Holmes E. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. Br J Cancer. 2015;112:1141-1156. [PMID: 25826224 DOI: 10.1038/bjc.2015.38] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 12.2] [Reference Citation Analysis]
18 Park J, Kim HT, Lee S, Lee Y, Choi U, Kang JH, Choi SY, Kang T, Choi M, Kwon O. Differential expression of intermediate filaments in the process of developing hepatic steatosis. Proteomics 2011;11:2777-89. [DOI: 10.1002/pmic.201000544] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
19 Sun S, Lee D, Ho AS, Pu JK, Zhang XQ, Lee NP, Day PJ, Lui WM, Fung CF, Leung GK. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. Neuro Oncol 2013;15:562-77. [PMID: 23444257 DOI: 10.1093/neuonc/not005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
20 Tomiyama L, Kamino H, Fukamachi H, Urano T. Precise epitope determination of the anti-vimentin monoclonal antibody V9. Mol Med Rep 2017;16:3917-21. [PMID: 28765898 DOI: 10.3892/mmr.2017.7102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Butera G, Brandi J, Cavallini C, Scarpa A, Lawlor RT, Scupoli MT, Marengo E, Cecconi D, Manfredi M, Donadelli M. The Mutant p53-Driven Secretome Has Oncogenic Functions in Pancreatic Ductal Adenocarcinoma Cells. Biomolecules 2020;10:E884. [PMID: 32526853 DOI: 10.3390/biom10060884] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Huang D, Yuan W, Li H, Li S, Chen Z, Yang H. Identification of key pathways and biomarkers in sorafenib-resistant hepatocellular carcinoma using bioinformatics analysis. Exp Ther Med 2018;16:1850-8. [PMID: 30186410 DOI: 10.3892/etm.2018.6427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
23 Sun S, Wong TS, Zhang XQ, Pu JK, Lee NP, Day PJ, Ng GK, Lui WM, Leung GK. Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines. J Neurooncol. 2012;107:89-100. [PMID: 21979894 DOI: 10.1007/s11060-011-0729-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
24 Wójcik M, Ramadori P, Blaschke M, Sultan S, Khan S, Malik IA, Naz N, Martius G, Ramadori G, Schultze FC. Immunodetection of cyclooxygenase-2 (COX-2) is restricted to tissue macrophages in normal rat liver and to recruited mononuclear phagocytes in liver injury and cholangiocarcinoma. Histochem Cell Biol. 2012;137:217-233. [PMID: 22131058 DOI: 10.1007/s00418-011-0889-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
25 Vergara D, Simeone P, Franck J, Trerotola M, Giudetti A, Capobianco L, Tinelli A, Bellomo C, Fournier I, Gaballo A, Alberti S, Salzet M, Maffia M. Translating epithelial mesenchymal transition markers into the clinic: Novel insights from proteomics. EuPA Open Proteom 2016;10:31-41. [PMID: 29900098 DOI: 10.1016/j.euprot.2016.01.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
26 Zhou H, Xu J, Zhang C, Wen Y. Aberrant histone deacetylase 1 expression upregulates vimentin expression via an NF-κB-dependent pathway in hepatocellular carcinoma. Oncol Lett 2019;18:339-47. [PMID: 31289505 DOI: 10.3892/ol.2019.10309] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Ray S, Reddy PJ, Jain R, Gollapalli K, Moiyadi A, Srivastava S. Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics 2011;11:2139-61. [PMID: 21548090 DOI: 10.1002/pmic.201000460] [Cited by in Crossref: 155] [Cited by in F6Publishing: 143] [Article Influence: 15.5] [Reference Citation Analysis]
28 Guo Z, Hao T, Duan J, Wang S, Wei D. Electrochemiluminescence immunosensor based on graphene–CdS quantum dots–agarose composite for the ultrasensitive detection of alpha fetoprotein. Talanta 2012;89:27-32. [DOI: 10.1016/j.talanta.2011.11.017] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 6.0] [Reference Citation Analysis]
29 Wahb AMSE, El Kassas M, Khamis AK, Elhelbawy M, Elhelbawy N, Habieb MSE. Circulating microRNA 9-3p and serum endocan as potential biomarkers for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol 2021; 13(11): 1753-1765 [DOI: 10.4254/wjh.v13.i11.1753] [Reference Citation Analysis]
30 Wong KF, Wo J, Ho D, Poon RT, Casasnovas JM, Luk JM. Prophylactic uses of integrin CD18-βA peptide in a murine polymicrobial peritonitis model. World J Gastroenterol 2010; 16(21): 2648-2656 [PMID: 20518087 DOI: 10.3748/wjg.v16.i21.2648] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
31 Shevchenko VE, Kovalev SV, Arnotskaya NE, Kudryavtsev IA. Identification of Potential Lung Cancer Biomarkers by Liquid Chromatography Tandem Mass Spectrometry-Based Proteomics Analysis of Secretomes of Two Lung Cancer Cell Lines. Eur J Mass Spectrom (Chichester) 2013;19:377-89. [DOI: 10.1255/ejms.1247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Scatena R, Bottoni P, Giardina B. Circulating tumour cells and cancer stem cells: a role for proteomics in defining the interrelationships between function, phenotype and differentiation with potential clinical applications. Biochim Biophys Acta 2013;1835:129-43. [PMID: 23228700 DOI: 10.1016/j.bbcan.2012.12.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
33 Strouhalova K, Přechová M, Gandalovičová A, Brábek J, Gregor M, Rosel D. Vimentin Intermediate Filaments as Potential Target for Cancer Treatment. Cancers (Basel) 2020;12:E184. [PMID: 31940801 DOI: 10.3390/cancers12010184] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 47.0] [Reference Citation Analysis]
34 Slany A, Haudek-prinz V, Zwickl H, Stättner S, Grasl-kraupp B, Gerner C. Myofibroblasts are important contributors to human hepatocellular carcinoma: Evidence for tumor promotion by proteome profiling: Proteomics and 2DE. ELECTROPHORESIS 2013;34:3315-25. [DOI: 10.1002/elps.201300326] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
35 Kanaji N, Kadota K, Tadokoro A, Inoue T, Watanabe N, Haba R, Kadowaki N, Ishii T. Serum CYFRA 21-1 but not Vimentin is Associated with Poor Prognosis in Advanced Lung Cancer Patients. Open Respir Med J 2019;13:31-7. [PMID: 31908686 DOI: 10.2174/1874306401913010031] [Reference Citation Analysis]
36 Lee NP. The Blood-Biliary Barrier, Tight Junctions and Human Liver Diseases. In: Cheng CY, editor. Biology and Regulation of Blood-Tissue Barriers. New York: Springer; 2013. pp. 171-85. [DOI: 10.1007/978-1-4614-4711-5_8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
37 Boutz DR, Collins PJ, Suresh U, Lu M, Ramírez CM, Fernández-Hernando C, Huang Y, Abreu Rde S, Le SY, Shapiro BA. Two-tiered approach identifies a network of cancer and liver disease-related genes regulated by miR-122. J Biol Chem. 2011;286:18066-18078. [PMID: 21402708 DOI: 10.1074/jbc.m110.196451] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
38 Zhang X, Thiéfin G, Gobinet C, Untereiner V, Taleb I, Bernard-chabert B, Heurgué A, Truntzer C, Ducoroy P, Hillon P, Sockalingum GD. Profiling serologic biomarkers in cirrhotic patients via high-throughput Fourier transform infrared spectroscopy: toward a new diagnostic tool of hepatocellular carcinoma. Translational Research 2013;162:279-86. [DOI: 10.1016/j.trsl.2013.07.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
39 Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68:3033-3046. [PMID: 21637948 DOI: 10.1007/s00018-011-0735-1] [Cited by in Crossref: 751] [Cited by in F6Publishing: 725] [Article Influence: 75.1] [Reference Citation Analysis]
40 Cho WC. Proteomics and translational medicine: molecular biomarkers for cancer diagnosis, prognosis and prediction of therapy outcome. Expert Rev Proteomics 2011;8:1-4. [PMID: 21329422 DOI: 10.1586/epr.10.108] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
41 Yu MB, Guerra J, Firek A, Langridge WHR. Extracellular vimentin modulates human dendritic cell activation. Mol Immunol 2018;104:37-46. [PMID: 30399492 DOI: 10.1016/j.molimm.2018.09.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
42 Pocsfalvi G, Votta G, De Vincenzo A, Fiume I, Raj DAA, Marra G, Stoppelli MP, Iaccarino I. Analysis of Secretome Changes Uncovers an Autocrine/Paracrine Component in the Modulation of Cell Proliferation and Motility by c-Myc. J Proteome Res 2011;10:5326-37. [DOI: 10.1021/pr200584y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
43 Wong K, Xu Z, Chen J, Lee NP, Luk JM. Circulating markers for prognosis of hepatocellular carcinoma. Expert Opinion on Medical Diagnostics 2013;7:319-29. [DOI: 10.1517/17530059.2013.795146] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
44 Bottoni P, Isgrò MA, Scatena R. The epithelial-mesenchymal transition in cancer: a potential critical topic for translational proteomic research. Expert Rev Proteomics 2016;13:115-33. [PMID: 26567562 DOI: 10.1586/14789450.2016.1112742] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
45 Zhu S, Zhang X, Gao M, Hong G, Yan G, Zhang X. Developing a strong anion exchange/RP (SAX/RP) 2D LC system for high-abundance proteins depletion in human plasma. Proteomics 2012;12:3451-63. [DOI: 10.1002/pmic.201200036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
46 Luk JM, Liu AM. Proteomics of hepatocellular carcinoma in Chinese patients. OMICS 2011;15:261-6. [PMID: 21348761 DOI: 10.1089/omi.2010.0099] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
47 Chan LK, Ng IO. Proteomic profiling in liver cancer: another new page. Transl Gastroenterol Hepatol. 2019;4:47. [PMID: 31304424 DOI: 10.21037/tgh.2019.06.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Uto H, Kanmura S, Takami Y, Tsubouchi H. Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers. Proteome Sci 2010;8:70. [PMID: 21192835 DOI: 10.1186/1477-5956-8-70] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]